We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
APP Pharmaceuticals has received final approval from the FDA for its ANDA to market a generic version of Roche’s Kytril in 1-mg/mL, 1-mL single-dose and 1-mg/mL, 4-mL multiple-dose vials, according to APP.